ClinicalTrials.gg
RecruitingNCT06911632MOMENTOUSUpdated Nov 3, 2026

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

An interventional study of ECG-based AI Device - Results Returned to Investigator and Echocardiogram and Right Heart Catheterization in Pulmonary Hypertension and Interstitial Lung Disease (ILD), sponsored by Tempus AI. Recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Tempus AI · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 3, 20264 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
4th of 286
900 · median 30
Started
2025
with 19 others
No phase
42 of 397
12 open now
Primary completion
2028-05
later than 49 of 84 live
Registered
361st of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 4th largest by planned enrollment of the 286 interventional ones that give a count, is one of 20 that started in 2025, is one of 42 with no phase, reaches primary completion later than 49 of the 84 other live ones, and was the 361st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Read the detailed description

The goal of this study is to evaluate the use of an ECG-based AI device that may help predict if participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension (PH). The study seeks to determine whether use of the device increases the rate of new PH diagnoses over a period of 6 months as compared to current standard of care.

The study will recruit participants with ILD from lung disease clinics who will each receive a 12-lead ECG (a test that measures the electrical activity of the heart) following consent. The device will analyze the 12-lead ECG results to identify participants that are at high risk of having undiagnosed PH.

Participants will be randomly assigned to either the Device or Control group. For participants in the Device group investigators will receive the results of the device. In the Control group investigators will not receive the results of the device. Additionally, participants in the Device group identified as "high risk" by the device will receive a transthoracic echocardiogram and a right heart catheterization (RHC). Participants in the Device group who are not high risk and all participants in the Control group will not receive these additional tests as part of the study, but will receive standard of care treatment as determined by their physicians, which may include an echocardiogram or RHC if clinically indicated.

03

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease (ILD)

Keywords

  • Pulmonary Hypertension
  • Interstitial lung disease (ILD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older at the time of consent
  • A known diagnosis of interstitial lung disease
  • Diffusing capacity for carbon monoxide (DLCO) \<30% predicted, collected within 6 months prior to consent
  • Willing and able to provide and undergo all study-specific procedures, including echo and RHC, if required

Exclusion criteria

Exclusion Criteria:

  • A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
  • A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
  • LV ≤ 40% on most recent echo or cardiac MRI, if available
  • Unclassifiable Tempus PH risk result after up to 2 ECG acquisitions
  • A to RHC exists (for example, pregnancy or mechanical right heart valve)
  • Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
  • There is a severe concomitant illness limiting to less than 6 months (at the discretion of the investigator)
  • There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    High Risk Device

    The device result will be returned to the treating provider and participants will undergo a study sponsored diagnostic work-up consisting of a transthoracic echocardiogram and an RHC.

    Device: ECG-based AI Device - Results Returned to Investigator · Procedure: Echocardiogram and Right Heart Catheterization

  • Experimental
    Not High Risk Device

    The device result will be returned to the treating provider. Participants will continue to be evaluated for PH according to the current standard of care with any diagnostic procedures ordered at the discretion of the treating provider.

    Device: ECG-based AI Device - Results Returned to Investigator

  • Other
    High Risk Control Arm

    The device result will not be returned to the treating provider. Participants will continue to be evaluated for PH according to the current standard of care with any diagnostic procedures ordered at the discretion of the treating provider.

    Device: ECG-based AI Device - Results Not Returned to Investigator

  • Other
    Not High Risk Control Arm

    The device result will not be returned to the treating provider. Participants will continue to be evaluated for PH according to the current standard of care with any diagnostic procedures ordered at the discretion of the treating provider.

    Device: ECG-based AI Device - Results Not Returned to Investigator

Interventions

  • DeviceECG-based AI Device - Results Returned to Investigator

    An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.

  • ProcedureEchocardiogram and Right Heart Catheterization

    Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart

  • DeviceECG-based AI Device - Results Not Returned to Investigator

    An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.

06

What researchers measure

Primary outcomes

  1. Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.

    Mean pulmonary artery pressure (mPAP) \> 20 mm Hg and pulmonary vascular resistance (PVR) \> 2 Wood units

    Time frame: Through study completion, approximately 6 months

Secondary outcomes

  1. Proportion of participants receiving a new diagnosis of PH within the Device group compared to the Control group.

    mPAP \> 20 mm Hg and PVR \> 2 Wood units

    Time frame: Through study completion, approximately 6 months

  2. Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the Not high risk Device group.

    mPAP \> 20 mm Hg and PVR \> 2 Wood units

    Time frame: Through study completion, approximately 6 months

07

Study locations

41 of 41 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

Of 150 interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Jul 23, 2025
Primary completionEst.
May 2028
CompletionEst.
Jul 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (4 United States)
  • University of Arkansas · Little Rock, United States
  • Corewell Health · Royal Oak, United States
  • HCA Research Institute - Methodist Hospital · San Antonio, United States
  • The University of Texas Health Science Center Houston · Houston, United States
across 2 updates, Oct 9, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added
    Show site
    • The University of Texas Health Science Center Houston · Houston, United States
  2. Oct 9, 2026
    3 sites added
    Show 3 added (3 United States)
    • University of Arkansas · Little Rock, United States
    • Corewell Health · Royal Oak, United States
    • HCA Research Institute - Methodist Hospital · San Antonio, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06911632
Lead sponsor
Tempus AI
Collaborators
United Therapeutics
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Jul 23, 2025
Primary completion
May 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Momentous Study
Contact
momentous-study@tempus.com
(833) 514-4187

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion